Skip to main content
. Author manuscript; available in PMC: 2014 Jan 20.
Published in final edited form as: Cancer Res. 2010 May 18;70(11):4539–4549. doi: 10.1158/0008-5472.CAN-09-4658

Figure 1.

Figure 1

VSV activates bone marrow cytotoxicity against B16ova. A, in vitro coculture between tumor cells and bone marrow cells; NAb: neutralizing anti-VSV immune serum. B, light microscopy of cocultures (from A) of B16ova cells 24 h following treatment with (i) VSV MOI 0.1 (no bone marrow), (ii) VSV+NAb (no bone marrow), (iii) bone marrow+NAb, (iv) bone marrow cells alone (no VSV or Nab), or (v) bone marrow (BM)+VSV+NAb.